Hutchinson Ian, Jennings Sharon A, Vishnuvajjala B Rao, Westwell Andrew D, Stevens Malcolm F G
Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, Nottingham NG7 2RD, UK.
J Med Chem. 2002 Jan 31;45(3):744-7. doi: 10.1021/jm011025r.
A series of water-soluble L-lysyl- and L-alanyl-amide prodrugs of the lipophilic antitumor 2-(4-aminophenyl)benzothiazoles has been synthesized to address formulation and bioavailability issues related to the desired parenteral administration of the chosen clinical candidate. The prodrugs exhibit the required pharmaceutical properties of good water solubility (in weak acid) and stability at ambient temperature and degradation to free base in vivo. The lysyl-amide of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (NSC 710305, 6d) has been selected for phase 1 clinical evaluation.
为了解决与所选临床候选药物期望的肠胃外给药相关的制剂和生物利用度问题,已合成了一系列亲脂性抗肿瘤药物2-(4-氨基苯基)苯并噻唑的水溶性L-赖氨酰和L-丙氨酰胺前药。这些前药具有所需的药物性质,即在弱酸中具有良好的水溶性、在环境温度下稳定且在体内降解为游离碱。2-(4-氨基-3-甲基苯基)-5-氟苯并噻唑(NSC 710305,6d)的赖氨酰胺已被选用于1期临床评估。